25 January 2022
It is with great pleasure that EASL announces that their first open-access journal JHEP Reports has been accepted into Clarivate’s Science Citation Index Expanded (SCIE) and Journal Citation Reports. This means that the Journal will receive its first impact factor in the summer of 2022, only three years after the publication of its first issue in May 2019.
The impact factor is an important measure of the frequency with which the average article in a journal is cited in a given year, contributing to the standing of a journal within the scientific community.
JHEP Reports is an open access, online-only, companion title to the highly respected Journal of Hepatology. Its original aim was to provide a respected channel for the publication of innovative basic, translation and clinical studies in hepatology.
This major milestone is a testament to the dedication and hard work of the editorial team, JHEP Reports was developed to provide an alternative home for innovative research in hepatology and the acceptance of our Journal by Clarivate represents an important step towards this goal. The recently published, and novel, Patient Guideline is an excellent example of how the Journal is positioning itself for scientists, clinicians, and patients within a changing healthcare landscape,
said Editor-in-Chief of JHEP Reports, Prof. Jessica Zucman-Rossi.
EASL expresses its gratitude to all authors for submitting and entrusting the Journal with their research, to the reviewers who have given their time and expertise, and to the editorial team who steered the Journal to this wonderful achievement, showing the world that JHEP Reports is a key resource in the field of hepatology,
said EASL Secretary General Prof. Thomas Berg.
This is the start of another exciting phase for JHEP Reports. The ingenuity of our editorial team, the expertise of our reviewers and the quality of our authors’ research are continuing to enhance both the value and reputation of our Journal,
concluded Prof. Zucman-Rossi.
About JHEP Reports
JHEP Reports is an open-access companion title to the highly-respected Journal of Hepatology. It publishes original papers, reviews, and letters to the Editor concerned with basic, translation and clinical research in the field of hepatology. JHEP Reports is an innovative journal publishing articles on global issues in hepatology, with specific focus on clinical trials, novel diagnostics, precision medicine and therapeutics, cellular and molecular research, metabolism, cancer, microbiome, systems biology, epidemiology, and biotechnology advances and devices
About The European Association for the Study of the Liver (EASL) – The Home of Hepatology
EASL, the European Association for the Study of the Liver, founded in 1966, is a medical association dedicated to pursuing excellence in liver research, to the clinical practice of liver disorders, and to providing education to all those interested in hepatology. As of 2021, EASL serves more than 4,500 members.
EASL engages globally with all stakeholders in the field of hepatology, worldwide. Our aim is to spread knowledge and expertise in best practices and the latest scientific breakthroughs in this field. We advocate for the benefit of patients and advise European and national health authorities. EASL runs topical conferences, schools, and related educational meetings. Our journals, the Journal of Hepatology and JHEP Reports, provide an international forum for the publication of original articles, reviews, and letters to the Editor, describing the latest science in hepatology. Our eLearning hub, EASL Campus, offers more than 4,100 resources on hepatology and liver research.
Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world’s most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect, and commercialise their inventions, using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.